The potential role of herbal extract Wedelolactone for treating particle-induced osteolysis: an in vivo study. was written by Lu, Yung-Chang;Chang, Ting-Kuo;Lin, Tzu-Chiao;Yeh, Shu-Ting;Fang, Hsu-Wei;Huang, Chun-Hsiung;Huang, Chang-Hung. And the article was included in Journal of orthopaedic surgery and research in 2022.HPLC of Formula: 524-12-9 The following contents are mentioned in the article:
BACKGROUND: Osteolysis is one of the most prevalent clinical complications affecting people who undergo total joint replacement (TJR). Wedelolactone (WDL) is a coumestan compound derived from the Wedelia chinensis plant and has been demonstrated to exhibit anti-inflammatory properties. This study aimed to investigate the oral administration of WDL as a potential treatment for particle-induced osteolysis using a well-established mice calvarial disease model. METHODS: Thirty-two C57BL/6Â J mice were randomized into four groups: Sham, vehicle, osteolysis group with oral WDL treatment for 4Â weeks (WDL 4w), and osteolysis group treated for 8Â weeks (WDL 8w). Micro-CT was used to quantitatively analyze the bone mineral density (BMD), bone volume/tissue volume (BV/TV) and trabecular bone thickness (Tb.Th). Osteoclast numbers were also measured from histological slides by two investigators who were blind to the treatment used. RESULTS: The results from micro-CT observation showed that BMD in the WDL 8w group improved significantly over the vehicle group (pâ?lt;â?.05), but there was no significant difference between WDL 4w and 8w for BV/TV and Tb.Th. Osteoclast numbers in the WDL 4w group were also lower than the vehicle group (pâ?lt;â?.05), but the difference between WDL 8w and 4w groups was not significant. CONCLUSIONS: Particle-induced osteolysis is an inevitable long-term complication after TJR. The results of this animal study indicate that an oral administration of WDL can help reduce the severity of osteolysis without adverse effects. This study involved multiple reactions and reactants, such as 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c]chromen-6-one (cas: 524-12-9HPLC of Formula: 524-12-9).
1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c]chromen-6-one (cas: 524-12-9) belongs to benzofurans derivatives. Benzofuran derivatives are one of the most important oxygen-containing heterocycles. Benzofurans have also made significant and distinctive contributions to biology. They exhibit several biological activities that range from antiviral, antimicrobial, antitumor, anti-inflammatory.HPLC of Formula: 524-12-9
Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem